💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Novartis corrects chairman's comments about kickbacks case

Published 03/24/2021, 11:26 AM
Updated 03/24/2021, 11:30 AM
© Reuters.

By John Miller

ZURICH (Reuters) - Novartis on Wednesday had to correct comments made by Chairman Joerg Reinhardt to a Swiss newspaper, because his portrayal of conduct that led to a $678 million U.S. settlement over kickbacks last year risked violating the agreement.

Novartis's settlement with the U.S. Justice Department in July 2020 resolved decade-old charges that it organised thousands of sham events, lavished doctors with speaker fees and wined and dined them to boost drug prescriptions.

In a SonntagsBlick interview on March 6, however, Reinhardt objected when a reporter said Novartis had bribed U.S. doctors.

"I don't want to let the term 'bribery' stand without comment," Reinhardt told SonntagsBlick. "Doctors were invited to scientific events. We were possibly here and there too generous."

Reinhardt's comments were inaccurate, said Novartis, whose Chief Executive Vas Narasimhan has prioritized boosting Novartis's ethics performance, including by revising bonus schemes, after scandals over two decades that have cost it some $2 billion hurt its reputation.

"Mr. Reinhardt described the programs as scientific events and stated that the company may have been too generous on occasion to the doctors in attendance," Novartis said in a statement.

"These comments were inaccurate and inconsistent with the admissions of conduct that Novartis made in its settlement agreement."

Based on its commitments under the settlement, Novartis said it proactively contacted the U.S. Justice Department after concluding Reinhardt's interview comments were inaccurate and issued the correction after discussions with prosecutors over remedying the issue.

"Mr. Reinhardt's statements were not intended to minimize or dispute Novartis' admissions of conduct," Novartis said, adding that Reinhardt also offered reassurances in the SonntagsBlick interview that the alleged U.S. practices 'are history and will not be repeated.' "

"Novartis reiterates fully the acknowledgements it made in its agreement," the company added.

© Reuters. FILE PHOTO: The logo of Swiss drugmaker Novartis is pictured at the French company's headquarters in Rueil-Malmaison

In its U.S. settlement, Novartis was required to reduce paid-speaker programs and hold them virtually, to reduce potential improprieties.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.